​

MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$9.52

52W Range

$5.95 - $62.75

50D Avg

$35.94

200D Avg

$41.83

Market Cap

$639.46M

Avg Vol (3M)

$4.31M

Beta

1.10

Div Yield

-

MLTX Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

100

IPO Date

Oct 20, 2020

Website

MLTX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
License$299.60M$299.60M$299.60M

Fiscal year ends in Dec 24 | Currency in USD

MLTX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-54.12M$-65.06M
Net Income$-120.68B$-36.01M$-64.51M
EBITDA-$-54.11M$-65.05M
Basic EPS$-1.92K$-0.73$-2.20
Diluted EPS$-1.92K$-0.73$-2.20

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 8:45 PM

Peer Comparison

TickerCompany
KALVKalVista Pharmaceuticals, Inc.
RGNXREGENXBIO Inc.
GOSSGossamer Bio, Inc.
CMPXCompass Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
VSTMVerastem, Inc.
NRIXNurix Therapeutics, Inc.
ATXSAstria Therapeutics, Inc.
KODKodiak Sciences Inc.
SVRASavara Inc.